A Randomized, Double-Blind, Placebo-Controlled Study of Omalizumab for Idiopathic Anaphylaxis

Clinical trial NCT00890162 · COMPLETED

Trial details

NCT number: NCT00890162
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Anaphylaxis Hypotension Bronchospasm Angioedema

Start date: 2009-04-27
Primary completion: 2018-07-31
Enrollment: 16

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.